Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.